Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

 – Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – 

Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with her investment as founding member of Goose Capital.

Read more at globenewswire.com